MedTrace Logo

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-09-18

Study results available
· View outcomes & findings →

Summary

To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.

Conditions

Interventions

DRUG

Amrubicin

40, 60, or 80 mg/m2 intravenous (IV)

DRUG

Lenalidomide

15 mg daily by mouth

DRUG

Dexamethasone

40 mg weekly by mouth

DRUG

Aspirin

81 or 325 mg daily by mouth

DRUG

Pegfilgrastim

6 mg subcutaneous on Day 2

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Michaela Liedtke

    lead OTHER

Principal Investigators

  • Michaela Liedtke · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-07-31
Completion
2017-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01355705 on ClinicalTrials.gov